Cargando…
Improved Process for the Synthesis of 3-(3-Trifluoromethylphenyl)propanal for More Sustainable Production of Cinacalcet HCl †
Cinacalcet (I), sold as hydrochloride salt, is a calcimimetic drug which has been approved for the treatment of secondary hyperparathyroidism in patients with chronic renal disease and for the treatment of hypercalcemia in patients with parathyroid carcinoma. Here, an improved method for the synthes...
Autores principales: | Rathod, Vikas Damu, Paganelli, Stefano, Kočevar, Marijan, Krivec, Marko, Piccolo, Oreste |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458415/ https://www.ncbi.nlm.nih.gov/pubmed/37630295 http://dx.doi.org/10.3390/molecules28166042 |
Ejemplares similares
-
Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008) -
Iridium complexes of an ortho-trifluoromethylphenyl substituted PONOP pincer ligand
por: Poole, Ethan W., et al.
Publicado: (2022) -
Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Trial
Publicado: (2015) -
1-(2-Chlorobenzoyl)-3-(2-trifluoromethylphenyl)thiourea
por: Rauf, M. Khawar, et al.
Publicado: (2012) -
Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial
por: Wheeler, David C., et al.
Publicado: (2014)